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Abstract: Human papillomavirus (HPV) persistent infections are associated with cervical cancer and other
HPV-related diseases and tumors. Thus, the characterization of long lasting immunity to currently
available HPV vaccines is important. A total of 149 female subjects vaccinated with Cervarix or Gardasil
participated to the study and they were stratified according to age (10–12-year-old and 16–20-year-old).
Humoral immune responses (IgG and neutralizing antibody titers, antibody avidity) and circulating
memory B cells were analyzed after an average of 4–6 years from the third immunization. The humoral
responses against HPV-16 and HPV-18 (and HPV-6 and HPV-11 for Gardasil) were high in both age
groups and vaccines up to six years from the third dose. However, Cervarix induced significantly higher
and more persistent antibody responses, while the two vaccines were rather equivalent in inducing
memory B cells against HPV-16 and HPV-18. Moreover, the percentage of subjects with vaccine-specific
memory B cells was even superior among Gardasil vaccinees and, conversely, Cervarix vaccinated
individuals with circulating antibodies, but undetectable memory B cells were found. Finally, a higher
proportion of Cervarix-vaccinated subjects displayed cross-neutralizing responses against non-vaccine
types HPV-31 and HPV-45. Gardasil and Cervarix may, thus, differently affect long-lasting humoral
immunity from both the quantitative and qualitative point of view.
Keywords: 2vHPV vaccine; 4vHPV vaccine; IgG titers; Neutralizing antibodies; avidity index;
cross-neutralizing antibodies; B-elispot; memory B cells; adolescent girls; young adult women
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1. Introduction
Human papillomavirus (HPV) infection is the most frequent sexually transmitted viral infection,
which is associated with the occurrence of both benign and malignant lesions. There are more than
100 types of circulating HPVs and at least 14 are strongly associated with cervical cancer development
and known as high-risk types. Most sexually active women and men acquire HPV infection during
their lives and some can be infected more than once and co-infected with different types. The antibody
levels that are induced by natural infection are often low and the immune responses against reinfections
weak [1–3]. Although most HPV infections are transient and spontaneously cleared up within two
years after acquisition, chronic infections occur in nearly 10% of cases with a small proportion of these
infections proceeding to pre-cancerous and cancerous lesions. Persistent infection with high-risk HPV
types is the fourth major cause of cervical cancer worldwide and it is also associated with ano-genital
and oropharynx cancers, in both males and females, in a time frame of 15–20 years after acquisition or
even less (5–10 years) in persons with a weakened immune system. Oncogenic HPV-16 and HPV-18
are known to cause at least 70% of cervical cancers, whereas other high-risk types, such as HPV-31, 33,
39, 45, 51, 52, 56, 58, 59, and 68, cause a further 20% [4–6].
A vaccine that induces long-term immune responses and protection against oncogenic HPV types is
therefore of outmost importance in preventing cervical cancer and other HPV-related diseases and tumours.
Prophylactic HPV vaccines in widespread use since 2006/2007 [7,8] include the AS04-adjuvanted
bivalent vaccine (2vHPV; Cervarix, GSK, Verona, Italy) and the aluminium hydroxyphosphate sulfate
salt-adjuvanted quadrivalent vaccine (4vHPV; Gardasil, Merck, Rome, Italy) [9], which also exhibit some
degree of cross-protection against non-vaccine high-risk HPV types 31, 33, and 45 [10–12]. Further, in 2014,
a nonavalent vaccine (9vHPV; Gardasil 9, Merck) has been licensed by the FDA and then approved
in several countries [13]. Although manufactured by different methods, in insects (Cervarix) and yeasts
(Gardasil), all of the vaccines are formulated as virus-like particles (VLPs) of recombinant L1 capsid proteins
of oncogenic HPV-16 and HPV-18. However, the Gardasil vaccine also targets low-risk HPV-6 and HPV-11
that are responsible for 90% of genital warts and laryngeal papillomas and the Gardasil 9 vaccine includes
the VLPs of other five oncogenic types (31, 33, 45, 52, 58). The main target of vaccination are young
girls from 9 to 12 years of age, before they become sexually active and exposed to the virus, although
concurrent implementation programs targeting older-ages broaden the coverage, as major risk for HPV
infection is in the years after sexual debut [14,15]. More recently, some countries have also started to
vaccinate boys, since vaccination prevents genital cancers and warts in both males and females [16,17].
Immune correlates of protection are not entirely clear yet, however experimental evidence indicate
neutralizing antibodies (nAbs) as the main mechanism of protection. All of the vaccines indeed elicit
high titres of potent, type-specific nAbs that prevent infection by transudation or exudation through
the epithelium at the site of infection [8,18,19] and induce protection against cervical cancer that is
associated to the vaccine HPV with approximately 100% efficacy [20–23]. Indeed, follow up studies report
long-term immune responses and protection up to 10–12 years for Cervarix and Gardasil [24–26] and up
to five years for Gardasil 9 [13,27]. However, continued monitoring is important in identifying potential
signals of waning, especially in women that are vaccinated after adolescence.
Here, we have compared the long-term immunogenicity of Cervarix and Gardasil vaccines in two
cohorts of preteen/adolescent girls (aged 10–12 years) and young adult women (aged 16–20 years),
vaccinated in the context of current vaccination and implementation programs (targeting older-ages),
to assess whether, and to what extent, the type of vaccine might impact the quality, quantity,
and maintenance of these responses in two age groups. Different types of humoral immune responses
(IgG and nAbs titers, antibody avidity, and memory B cell responses) were analysed after an average
of 4–6 years from the third immunization. Indeed, experience with other vaccines indicate that both
circulating antibodies and memory B cells may mediate protection and, in some cases, vaccine efficacy
has been observed also in the absence of circulating antibodies [28]. As the role of memory B cells is
not completely clear in the case of HPV vaccination, we measured their persistence in comparison to
antibody levels and properties.
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2. Materials and Methods
2.1. Study Design
The aim of this investigator-initiated observational study was the evaluation and comparison
of memory immune responses of Cervarix and Gardasil vaccines after an average of 4–6 years
from the third vaccine boost in the target adolescent population of organized vaccination programs
(10–12-year-old, 10–12 y) and in young adults (16–20-year-old, 16–20 y) in Italy (Figure 1). In addition,
10–12 year-old girls (n = 53) that were vaccinated with Cervarix were enrolled at months 1–6 after the third
immunization. Enrolment was carried out at the public health districts of Padova (Veneto region)
and Bologna (Emilia-Romagna region), where Gardasil and Cervarix, respectively, were offered
by organized vaccination (9–12-year-old) and implementation (older ages) programs. In each district,
girls who had previously completed the vaccination schedule were invited by letter to participate
in the study, which consisted in blood sampling, to measure the persistence of immune response
elicited by vaccination. The exclusion criteria were fever and other symptoms of active infection
in the three weeks before blood collection, presence of chronic inflammatory diseases, immunosuppressive
therapy, and pregnancy. Unvaccinated, aged-matched healthy donors (n = 24) were also enrolled
as controls to establish the cut-off of the immunological assays. The Ethics Committees of Padova
University-Hospital and Bologna St Orsola-Malpighi University Hospital (Protocol no 2413P) approved
the study and conducted according to the principles expressed in the Declaration of Helsinki.
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Figure 1. Study groups. For each age and vaccine group, the number of subjects, their median age 
(with interquartile range), and the time of sample collection after the third immunization (presented 
as median and interquartile range) are shown. 
2.2. Samples Purification 
Whole peripheral blood was collected in spray-coated sodium citrate tubes for the purification 
of plasma and peripheral blood mononuclear cells (PBMCs). Briefly, whole blood was centrifuged at 
2500 rpm (Megafuge 1.0R, Heraeus) for 7 min. to collect plasma, whereas the cellular fraction was 
loaded on Ficoll density gradient (GE Healthcare) to purify PBMCs, as previously described [29,30]. 
Plasma was stored at −20 °C and purified PBMCs were suspended in 90% foetal bovine serum (FBS) 
(Lonza) and 10% DMSO (Sigma-Aldrich) and then preserved in liquid nitrogen until use. A small 
aliquot of blood was also collected to obtain sera and then stored at −20 °C until use. 
2.3. Plasmids 
Dr. John T. Schiller kindly provided plasmids p6sheLLr+, p16sheLL, and p18sheLL, containing 
L1/L2 genes of HPV6, 16 and 18 (Laboratory of Cellular Oncology, NIH, Bethesda), whereas Dr. 
Martin Müller kindly provided plasmid p11L1h containing the L1 gene of HPV11 (German Cancer 
Research Center, Heidelberg). Plasmid DNAs were amplified in XL-Gold ultracompetent cells 
(Stratagene) and purified by means of a commercial kit (Plasmid Maxi kit, Qiagene, Milan, Italy). 
Figure 1. Study groups. For each age and vaccine group, the number of subjects, their median age
(with interquartile range), and the time of sample collection after the third immunization (presented as median
and interquartile range) are shown.
2.2. Samples Purification
Whole peripheral blood was collected in spray-coated sodium citrate tubes for the purification
of plasma and peripheral blood m nonuclear cells (PBMC ). Briefly, whole lood was centrifuged
at 2500 rpm (Megafuge 1.0R, Heraeus) for 7 min. to collect plasma, whereas the cellular fraction w s
loaded on Ficoll density gradient (GE Healthcare) t purify PBMCs, as previously described [29,30].
Pl sma was stored at −20 ◦C and purified PBMCs were suspended in 90% foetal bovine serum (FBS)
(Lonz ) and 10% DMSO (Sigma-Aldr ch) and then pre erv d in liquid nitrogen until use. A small
aliquot of blood was also collected to obtain sera a d then stored at −20 ◦C until use.
2.3. Plasmids
Dr. John T. Schiller kindly provided plasmids p6sheLLr+, p16sheLL, and p18sheLL, containing
L1/L2 genes of HPV6, 16 and 18 (Laboratory of Cellular Oncology, NIH, Bethesda), whereas Dr. Martin
Müller kindly provided plasmid p11L1h containing the L1 gene of HPV11 (German Cancer Research
Center, Heidelberg). Plasmid DNAs were amplified in XL-Gold ultracompetent cells (Stratagene)
and purified by means of a commercial kit (Plasmid Maxi kit, Qiagene, Milan, Italy).
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2.4. VLPs Preparation
The preparation and purification of HPV type-specific virus like particles (VLPs) was
undertaken according to the protocol of Buck et al. [31]. The 293TT cell line was kindly
provided by John T. Schiller (NIH, Bethesda) and then grown in Dulbecco’s modified Eagle’s
Medium (DMEM) (Gibco Life Technologies) containing 10% FBS, 1% antibiotic-antimicotic solution,
1% glutamax, 1% non-essential aminoacids (all from Gibco Life Technologies), and 250 µg/mL
hygromycin B (Sigma-Aldrich). For each HPV type-specific VLP, 293TT cells (7 × 106) were seeded
in 75 cm2 flasks and incubated 16–18 h at 37 ◦C up to 50% confluence. Cells were lipofected
(Lipofectamin 2000, Invitrogen) with 20 µg of plasmid DNA, according to manufacturer’s instructions,
which were incubated at 37 ◦C and then collected 48 h later. The cells were washed in Dulbecco’s
phosphate buffered saline (D-PBS) containing 9.5 mM MgCl2, transferred to new eppendorf tubes
and centrifuged at 2000 rpm (Centrifuge 5418R, Eppendorf) for 7 min. The cellular pellet was
resuspended in D-PBS (1.5× the cellular volume) and then lysed with Triton X-100 (1/20 of the volume),
0.1% Benzonase (Sigma–Aldrich, Milan, Italy) 0.1% Plasmid Safe (Epicentre, Madison, WI, USA),
and 1 M ammonium sulphate (pH 9) (1/40 of the volume) at 37 ◦C for 24 h. The cell lysate was added
with 0.17 M NaCl, incubated on ice for 20 min. and centrifuged at 10,000 rpm at 4 ◦C. The supernatant
was left on ice for two hours and VLPs were purified by means of an iodixanol gradient (Sigma–Aldrich)
at 50,000 rpm for 3.5 h (rotor SW55ti, Beckman Coulter, Milan, Italy). Fractions were collected from
the bottom of the tube, read for protein concentration (BCA protein assay kit, Pierce, Milan, Italy),
and stored at −80 ◦C until use. The fractions were analyzed by SDS-PAGE, silver staining (Silver stain
kit, Pierce) and western blot using mouse anti-L1 primary IgG antibodies (HPV6/11: Antibodies-online;
HPV16: Santa Cruz Biotechnology, Dallas, Texas; HPV18: Abcam, Cambridge, UK), and an anti-mouse
HRP-secondary antibody (Abcam). For each type-specific VLP, all of the fractions positive for L1
derived from several transfections and purifications procedures were pooled together to obtain a single
type-specific VLP stock to be used for all immunological assays (IgG Elisa, avidity index, B-cell Elispot).
The protein concentration of each VLP stock was measured by BCA and disposable aliquots (25 µg)
were stored at −80 ◦C until use. All of the plasticware used in these procedures was siliconized
(StarLab, Milan, Italy).
2.5. Pseudovirion-Based Neutralization Assay (PBNA)
HPV type-specific pseudovirions (PsVs) encapsidating a SEAP reporter plasmid, their preparation
and purification, and the neutralization assays on serum samples were done as described previously [32].
Briefly, pseudovirions were obtained by the transfection of 293TT cells with equal amounts of p16shell,
p18shell, p31shell, or p45shell plasmids and the reporter pYSEAP plasmid. For the PBNA,
293TT cells were seeded in 96-well plates at a concentration of 30,000/well in neutralization buffer
(DMEM without phenol red, 10% of FBS, 1% of Glutamax™, 1% of non-essential amino-acids) grown
for 2–5 h at 37 ◦C and incubated with HPV PsVs alone or previously mixed with sera (two-fold
dilution from 1:40 to 1:163,840) in duplicate wells. After 72 h, cell supernatants were tested by using
the SEAP Reporter Gene Assay [32]. The neutralization titer was determined as the reciprocal of the final
dilution of serum that yielded <50% of mean RLU measured with PsVs alone and reported as ED50
(effective dose producing 50% response). The limit of quantification of the PBNA was set at 40 ED50.
The serum samples with neutralization titers equal or higher than 40 ED50 were considered to be
positive. Serum samples with neutralization titers less than 40 ED50 were assigned a value of 1 for
the purpose of geometric mean titer (GMT) calculation.
2.6. Determination of IgG Titers and Avidity
HPV type-specific IgG titers were measured by ELISA in 96-well plates (half area 96-well
plate high-bind, Fischer Scientific) that were pre-coated with 100 µL/well of each HPV type-specific
VLP (2 mg/mL in PBS) at 4 ◦C for 18–20 h. The plates were washed with 0.05% Tween in PBS,
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incubated with 1% bovine serum albumin (BSA, Sigma-Aldrich) in PBS for one hour and then with
plasma samples (50 µL) for two hours at 37 ◦C. The samples were serially diluted in PBS containing
1% BSA and then tested in duplicated wells. After extensive washing with 0.05% Tween in PBS,
the immunocomplexes were detected by incubation with a goat anti-human IgG-HRP (Abcam) for one
hour and the addition of ABTS substrate (Thermo Scientific, Milan, Italy) for 30 min. at 37 ◦C [33].
The optical density at 620 nm was determined with “Sunrise optical reader” (Tecan) and then analyzed
as previously described [34,35]. For each type-specific VLP, the cut-off values were determined by
analyzing the plasma of 24 unvaccinated healthy donors at 1:100 dilution as the mean OD (±3 SD):
0.374 for HPV-16; 0.346 for HPV-18; 0.388 for HPV-6; and, 0.346 for HPV-11. In each plate, blank
(wells with PBS-1% BSA alone), negative controls (wells with a pool of plasma of unvaccinated subjects),
and positive controls (wells with a pool of plasma of vaccinated subjects) were included.
The avidity of antigen-specific IgG was evaluated on selected samples with high IgG titers
by a modified ELISA [36,37]. Briefly, 96-well plates were coated with each HPV type-specific VLP,
washed, and then blocked with PBS-1% BSA, as described above. Based on the ELISA IgG titers,
selected plasma samples were diluted in PBS-1% BSA to obtain an OD of 1 ± 0.5, added (50 µL)
to the wells for two hours at 37 ◦C and washed as above. Negative and positive controls were included
in each plate. The plates were then incubated with 50 µL/well (duplicate wells) of 0.5 to 5 M GuHCl
for each sample (that removes the low avidity antibodies while high avidity antibodies remain bound)
for 15 min at room temperature under gentle agitation. Untreated samples and control wells were instead
incubated with PBS alone. After extensive washing, immune complexes were detected, as described
above. For each sample, the mean OD of duplicates were calculated and percentage of binding was
determined as ((treated OD/untreated OD) × 100). The avidity index (AI) is the extrapolated molar
concentration (M) of GuHCl required to reduce the absorbance of the untreated, control well by 50%.
2.7. Polyclonal Stimulation of Memory B-Cells and B-Cell Elispot
B-cell Elispot was standardized for several parameters, including the size of well-plates
(24 vs 96) for cell stimulation, the concentration of stimuli, the incubation time (5 vs 6 days)
(Supplementary Materials Figure S1A), and the number of cells/well (Figure S1B). Based on these
preliminary tests, frozen/thawed PBMCs were diluted in RPMI 1640 medium containing 10% FBS
(0.5 × 106/mL), seeded in 24-well plates (1 mL/well, duplicate wells), and grown unstimulated or
stimulated with ODN (3 µg/mL), S. aureus Cowan I (1:10.000), and Pokeweed (0.1 µg/mL) at 37 ◦C
for five days. The cells were then washed three times, counted by the Trypan blue exclusion method,
resuspended in culture medium (1.25 × 106/mL for antigen-specific B-cell Elispot; 6.25 × 104/mL for
total IgG B-cell Elispot) and added to 96-well Elispot plates. B-cell Elispot assays were performed by
means of a commercial “Human IgG B-cell Elispot” kit (Mabtech, Nacka Strand, Sweden), according to
the manufacturer’s instructions with some modifications. Briefly, 96-well plates (Maipswu, Millipore,
Milan, Italy) were pre-washed with 70% ethanol for two minutes and water, and then pre-adsorbed,
at 4 ◦C for 20–24 h, with 100µL of an anti-human IgG capture antibody (MT91/145; 15µg/mL) to quantify
the total number of B cells secreting IgG, or with 100 µL of each type-specific VLP (12.5 µg/mL)
to quantify the number of HPV type-specific B cells. After extensive washing with PBS, 200 µL
of unstimulated and stimulated PBMCs (1.25 × 106/mL) were seeded in each HPV type-specific plate
(duplicate wells), whereas 200, 100, and 50 µL of unstimulated and stimulated PBMCs (6.25 × 104/mL)
were added (duplicate wells) to the total IgG B-cell Elispot wells and, when required, volume adjusted
up to 200 µL with medium. In all plates, blank wells containing 200 µL of culture medium alone
were included. After incubation at 37 ◦C for two hours, the plates were washed and processed with
an anti-human-IgG-biotin detection antibody, according to the kit’s instructions. The spots were
counted while using an Elispot reader (AElvis, Hannover, Germany). The percentage of each HPV
type-specific memory B cells was calculated as [antigen-specific B cells (SFC/106 PBMC)/total memory
B cells (SFC/106 PBMC)] × 100.
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2.8. Statistical Analysis
The Mann–Whitney test was used to compare the difference between two independent groups, while
the correlations were analyzed by Spearman’s rank test. Differences in the frequencies were analyzed by
the Fisher’s exact probability test. P values of less than 0.05 were considered to be statistically significant.
Statistical analysis was performed while using the softwares R [38] and Rstudio [39] with the packages
Tidyverse [40] and Scales [41].
3. Results
3.1. Study Subjects
A total of 149 female subjects that were vaccinated with Cervarix (n = 98) (at month 0, 1, 6)
or Gardasil (n = 51) (at month 0, 2, 6) participated to the study and were stratified according to age.
The Cervarix and Gardasil cohorts included 64 and 31 subjects, respectively, in the 10–12 y group,
and 34 and 20 subjects, respectively, in the 16–20 y group. All of the participants were enrolled after
the third vaccine immunization (average 4–6 years) (Figure 1).
3.2. Long-Term Higher Antibody Levels in Cervarix-Vaccinated Women
The IgG seropositivity rates for HPV-16 and HPV-18 were significantly higher (91–100%) in both
Cervarix age groups as compared to the corresponding Gardasil cohorts (50–87%) after 4–6 years
from the third boost vaccination (Figure 2A), although the results in the 16–20 y group were not
significant for HPV-16. Hence, Cervarix ensures the long-term duration of humoral responses against
both HPV-16 and HPV-18 in all adolescents (10–12 y individuals) and in more than 90% of young
adults (16–20 y individuals), whereas the percentages of subjects with detectable IgG titers is lower
in Gardasil-vaccinated women, particularly in young adults for HPV-18 specific-IgG.
Similarly, HPV-16 and HPV-18 specific IgG titers were significantly higher in Cervarix-vaccinated
women for both age groups (mean IgG titers in 10–12 y: HPV-16=2352, HPV-18=1125; mean IgG
titers in 16–20 y: HPV-16 = 1429, HPV-18 = 439) as compared to Gardasil (mean IgG titers in 10–12 y:
HPV-16 = 255, HPV-18 = 119; mean IgG titers in-16–20 y: HPV-16 = 165, HPV-18 = 70) (Figure 2B).
In line with these results, the titers of nAbs after 4–6 years from vaccination were significantly
higher in Cervarix-vaccinated women of both age groups and HPV subtypes (values that range from
1480 to 6613 in the Cervarix-vaccinated women and from 436 to 2133 in the Gardasil-vaccinated
women), even though the difference was again not statistically significant for HPV-16 in the older age
group (Figure 3A). We next evaluated the presence and titers of cross-nAbs against HPV-31 and HPV-45.
Gardasil-vaccinated subjects did not show nAb against HPV-45, and only a small proportion (17%)
of those aged 10–12 y had HPV-31 cross-nAbs (Supplementary Materials Figure S2, titer range:
1–160). Conversely, 53 and 33% of Cervarix-vaccinated subjects aged 10–12 y and 16–20 y, respectively
(Supplementary Materials Figure S2), had HPV-31 cross-nAbs (titer range: 1–2560 for 10–12 y and 1–640
for 16–20 y). In addition, 23 and 3% of Cervarix-vaccinated subjects aged 10–12 y and 16–20 y
(Supplementary Materials Figure S2), respectively, had HPV-45 cross-nAbs (titer range: 1–160 for
10–12 y and 1–40 for 16–20 y).
Finally, the IgG avidity index was determined in a small subset of vaccinees and resulted slightly,
but significantly, higher for anti-HPV-16 antibodies in Cervarix-vaccinated women of both age groups
(4.4 and 4.2 for 10–12 y and 16–20 y groups, respectively) than the corresponding Gardasil cohorts
(four for both age groups). Instead, for anti-HPV-18 antibodies the avidity index was, in general,
lower (ranging from 2.7 to 2.9) than for anti-HPV-16, whereas it was comparable among Cervarix
and Gardasil vaccinees (Figure 3B).
Overall, these results indicate that Cervarix induces long-lasting humoral immunity in both
adolescents and young adult women against HPV-16 and HPV-18 subtypes. In contrast, after Gardasil
immunization, measurable antibodies against both subtypes are present in a lower number of vaccinated
subjects and at lower levels.
Vaccines 2020, 8, 26 7 of 18
Vaccines 2020, 8, 26 7 of 20 
 
 
Figure 2. Maintenance of HPV-16 and HPV-18 specific IgG. (A) Frequency of study subjects with 
detectable binding HPV-16 and HPV-18 specific IgG. (B) HPV-16 and HPV-18 specific IgG titers 
measured by ELISA shown as box and whiskers plots. Statistical comparisons were made using 
Fisher’s exact probability test (A) and Mann-Whitney test (B), ** P < 0.01, *** P < 0.001; for HPV-16 10–
12 y, n = 64 (Cervarix) and n = 31 (Gardasil); for HPV-16 16–20 y, n = 34 (Cervarix) and n = 20 (Gardasil); 
for HPV-18 10–12 y, n = 60 (Cervarix) and n = 31 (Gardasil); for HPV-18 16–20 y, n = 33 (Cervarix), and 
n = 20 (Gardasil). 
Figure 2. Maintenance of HPV-16 and HPV-18 specific IgG. (A) Frequency of study subjects with
detectable binding HPV-16 and HPV-18 specific IgG. (B) HPV-16 and HPV-18 specific IgG titers
measured by ELISA shown as box and whiskers plots. Statistical comparisons were made using Fisher’s
exact probability test (A) and Mann-Whitney test (B), ** P < 0.01, *** P < 0.001; for HPV-16 10–12 y,
n = 64 (Cervarix) and n = 31 (Gardasil); for HPV-16 16–20 y, n = 34 (Cervarix) and n = 20 (Gardasil);
for HPV-18 10–12 y, n = 60 (Cervarix) and n = 31 (Gardasil); for HPV-18 16–20 y, n = 33 (Cervarix),
and n = 20 (Gardasil).
3.3. Maintenance of Long-Term Memory B Cells in Both Cervarix- and Gardasil-Vaccinated Women
We next sought to analyze the persistence of vaccine-induced memory B cells by means
of B cell Elispot. Detectable HPV-16 and HPV-18 specific memory B cells were observed in a similar
proportion after both Cervarix and Gardasil vaccination in the 10–12 y groups (Figure 4A). Conversely,
and in contrast to serological measures, a higher percentage of Gardasil-vaccinated young women
maintained detectable memory B cells after vaccination, especially against HPV-16 (47% after Cervarix
and 90% after Gardasil vaccination, Figure 4A). Hence, Gardasil was more effective than Cervarix
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in the 16–20 y groups, while both vaccines ensure long-term memory B cells in more than 75%
of vaccinated adolescents.Vaccines 2020, 8, 26 8 of 20 
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for HPV-16 10–12 y, n = 62 (Cervarix) and n = 27 (Gardasil); for HPV-16 16–20 y, n = 31 (Cervarix) and 
n = 16 (Gardasil); for HPV-18 10–12 y, n = 58 (Cervarix) and n = 23 (Gardasil); for HPV-18 16–20 y, n = 
32 (Cervarix) and n=10 (Gardasil). (B) Avidity of HPV-16 and HPV-18 specific IgG, measured in a 
subgroup of ELISA responders, reported as molarity (M) and shown as box and whiskers plots; for 
HPV-16 10–12 y, n = 10 (Cervarix) and n = 7 (Gardasil); for HPV-16 16–20 y, n = 10 (Cervarix) and n = 
8 (Gardasil); for HPV-18 10–12 y, n = 10 (Cervarix); and, n = 7 (Gardasil); for HPV-18 16–20 y, n = 10 
(Cervarix) and n = 8 (Gardasil). Statistical comparisons were made while using Mann–Whitney test, * 
P < 0.05, ** P < 0.01, *** P < 0.001. 
Finally, the IgG avidity index was determined in a small subset of vaccinees and resulted 
slightly, but significantly, higher for anti-HPV-16 antibodies in Cervarix-vaccinated women of both 
age groups (4.4 and 4.2 for 10–12 y and 16–20 y groups, respectively) than the corresponding Gardasil 
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and n = 16 (Gardasil); for HPV-18 10–12 y, n = 58 (Cervarix) and n = 23 (Gardasil); for HPV-18 16–20 y,
n = 32 (Cervarix) and n = 10 (Gardasil). (B) Avidity of HPV-16 and HPV-18 specific IgG, measured
in a subgroup of ELISA responders, reported as molarity (M) and shown as box and whiskers plots;
for HPV-16 10–12 y, n = 10 (Cervarix) and n = 7 (Gardasil); for HPV-16 16–20 y, n = 10 (Cervarix)
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n = 10 (Cervarix) and n = 8 (Gardasil). Statistical comparisons were made while using Mann–Whitney
test, * P < 0.05, ** P < 0.01, *** P < 0.001.
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were made using Fisher’ exact probability test (A) and Mann–Whitney test (B), * P < 0.05, ** P < 0.01;
for HPV-16 1 –12 y, n = 61 (Cervarix) and n = 31 (Gard sil); for HPV-16 16–20 y, n = 32 (Cervarix)
and n = 20 (Gardasil); for HPV-18 10–12 y, n = 61 (Cervarix) and n = 31 (Gardasil); for HPV-18 16–20 y,
n = 32 (Cervarix) and n = 20 (Gardasil).
Despite this, Cervarix induced higher numbers of HPV-specific memory B cells, especially
in the younger age g oup with stati tical significance only for HPV-18 (Figure 4B).
Together, these data indicate that both vaccines induced long-lasting m mory B cells in the majority
of adolescents, although those that were vaccinated with Cervarix presented a higher number
of HPV-18-specific B cells. Conversely, HPV-16-specific B cells were maintained in a larger proportion
of Gardasil-vaccinated young adults.
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3.4. Maintenance of HPV-6 and HPV-11-Specific Responses After Vaccination with Gardasil
While Cervarix only contains antigens from two HPV strains (HPV-16 and HPV-18), Gardasil
also immunizes against HPV-6 and HPV-11 subtypes. HPV-6 specific IgG were maintained in 74%
of 10–12 y and in 55% of 16–20 y vaccinated individuals, while the proportion for HPV-11 responders
were higher (94% and 70%, respectively, Supplementary Materials Figure S3A). Notably, IgG titers
against both subtypes and in both age groups ranged from 105 to 406, thus in a range similar
to HPV-16 and HPV-18-specific, Gardasil-induced, IgG (compared Figure 2B with Supplementary
Materials Figure S3B). In addition, more than 85% individuals maintained HPV-6 and HPV-11 specific
memory B cells (Supplementary Materials Figure S3C,D). These results confirm that Gardasil induces
long-lasting memory B cells against all four HPV types, irrespective of the age of vaccination.
3.5. Antibodies and Memory B Cells are Independently Maintained After Vaccination
Analyses of circulating antibodies and B cells showed that Cervarix and Gardasil may
differently induce these two components of humoral immunity. In particular, the vast majority
of Cervarix-vaccinated individuals maintained HPV-specific IgG up to six years after vaccination.
However, more than 20% of those aged 10–12 years and more than 50% of those aged 16–20 years had
undetectable HPV-specific memory B cells (Figure 5). In addition, very few (3%) Cervarix-vaccinated
subjects (16–20 y) had detectable HPV-specific B cells, but not IgG (Figure 5). The latter observation
was more frequent in Gardasil-vaccinated subjects, as the percentage of individuals with detectable
HPV-specific memory B cells in the absence of circulating antibodies ranged from 10 to 35%, depending
on the age group and the HPV subtype (Figure 5). These data suggest that the maintenance of memory
B cells and circulating antibodies might be two independent phenomena. We measured the correlation
between memory B cell responses, circulating IgG, and nAbs to confirm this hypothesis. While the titers
of IgG and nAbs almost always significantly correlated for HPV-16 and HPV-18 for both vaccines
and age groups (except for HPV 16 in the Gardasil 16–20 y cohort) (Figure 6A), the same was not
true when analyzing the association between IgG titers and memory B lymphocytes. In particular,
the HPV-16-specific IgG and B cells levels were only significantly correlated in the 16–20 y age group for
both vaccines, while HPV-18-specific IgG and B cells were only significantly correlated in the 10–12 y,
Gardasil-vaccinated, subjects (Figure 6B). No significant correlation was instead observed between
HPV-specific nAbs and B cells levels, irrespective of the vaccine type, HPV-type and age group
(Figure 6C).
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Figure 5. Presence of circulating HPV-16 and HPV-18 specific IgG and memory B cells. Proportion
of subjects with both IgG and memory B cells, o l IgG, only memory B cells or undetectable responses
are shown for each vaccine and age group; for HPV-16 10–12 y, n = 40 (Cervarix) and n = 31 (Gardasil);
for HPV-16 16–20 y, n = 32 (Cervarix) and n = 20 (Gardasil); for HPV-18 10–12 y, n = 38 (Cervarix)
and n = 31 (Gardasil); for HPV-18 16–20 y, n = 31 (Cervarix) and n = 20 (Gardasil).
Vaccines 2020, 8, 26 11 of 18
Vaccines 2020, 8, 26 12 of 20 
 
 
Figure 6. Correlation between HPV-16 and HPV-18 specific IgG, nAbs and memory B cells. Correlation between (A) IgG and nAbs, (B) IgG and memory B cells and 
(C) nAbs and memory B cells. In each panel, data are stratified by age group (horizontal squares), type of vaccine (top-bottom squares) and HPV subtype (HPV-16, 
A, B, C, upper panels; HPV-18, A, B, C, bottom panels). Regression lines (dark, full lines) and 95% confidence interval (grey areas) are shown. Spearman’s rank 
correlation determined statistical significance.
Figure 6. Correlation between HPV-16 and HPV-18 specific IgG, nAbs and memory B cells. Correlation
between (A) IgG and nAbs, (B) IgG and memory B cells and (C) nAbs and memory B cells. In each panel,
data are stratified by age group (horizontal squares), type of vaccine (top-bottom squares) and HPV subtype
(HPV-16, A, B, C, upper panels; HPV-18, A, B, C, bottom panels). Regression lines (dark, full lines) and 95%
confidence interval (grey areas) are shown. Spearman’s rank correlation determined statistical significance.
The long-term maintenance of circulating IgG is thought to depend on the persistence of long-lived
plasma cells (LLPC) or on the differentiation of memory B cells into secreting plasma cells [42,43].
In the latter case, a correlation between antibody titers and memory B cell numbers should be observed.
We measured the correlation between HPV-specific IgG and memory B-cells in a cohort of Cervarix
vaccinated girls (10–12 y) at short time (1–6 months) after the third vaccine dose to understand if
the correlation observed only in one group of vaccinees (Figure 6B) is indicative of a cause-effect
relation, or due to the fact that the vaccine may induce both kinds of humoral immunity that may be
maintained at a similar extent, yet independently. As shown in Table 1, HPV-16 and HPV-18 specific IgG
titers and memory B cells both correlated at short, but not, long time after vaccination. This suggests
that the vaccine might induce both PCs and memory B cells in the first phases of the immune response,
but these two cell types will then follow different fates. Therefore, circulating antibodies and memory
B cells may be independently induced and maintained in a vaccine-specific manner.
Table 1. Correlation between antigen specific IgG titers and memory B cell frequencies.
Antigen Time after Vaccination N = Spearman’s r; p Value Slope (95% C.I.) R2
HPV-16
<6 months 53 0.4092; 0.0023 4892 (496; 9287) 0.08932
>2 years 40 0.06859; 0.6741 75 (−106; 257) 0.01839
HPV-18
<6 months 53 0.5310; <0.0001 3829 (1684; 5975) 0.2014
>2 years 38 −0.09464; 0.5719 −97 (−407; 213) 0.01109
4. Discussion
The results from this investigator-initiated observational study showed that the humoral responses
against HPV vaccine antigens remained detectable at high levels up to six years following the third
dose of either Cervarix or Gardasil vaccines. However, the percentages of seropositive subjects
and serological parameters (IgG titers, avidity indexes and neutralizing antibody titers) were, overall,
significantly higher in both Cervarix age groups when compared to the age-matched Gardasil
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recipients. The age of the recipients does not influence the differences between vaccines. Notably,
we used in-house produced VLPs for testing all samples to assess humoral and memory B cell responses,
thus excluding that the differences could be biased by a different antigen source. These data are
consistent with previous observations [44–46] and are likely dependent on the diverse formulations [47].
Indeed, Cervarix contains AS04 consisting of aluminium hydroxide and MPL, a detoxified derivative
of the immunomodulatory cell wall lipopolysaccharide (LPS) molecule of the Gram negative Salmonella
Minnesota [48] and an agonist of Toll-like receptor (TLR4), which activates the innate immune
response [49] and leads to prolonged activation of APCs [50]. Instead, Gardasil only contains
the aluminium hydroxyphosphate sulfate adjuvant. Additionally, in agreement with previous
observations [45], immune responses against HPV-16 were consistently higher than those against
HPV-18 in all Cervarix and Gardasil vaccinated subjects of both age groups. Notably, HPV-18 avidity
indexes resulted in being comparable among Cervarix and Gardasil vaccinees implying similar strength
of HPV-18 IgG binding independent from the type of vaccine in the long-term after vaccination.
The results also indicated that some of the analyzed immunological parameters and percentage
of seropositive subjects in the pre-teen cohorts (10–12 y) tended to be higher than in the young adults
cohorts (16–20 y) for both vaccines, which confirmed that the older age of the women enrolled is
a parameter that might affect immunogenicity [51–54]. We also observed high levels of anti-HPV-6
and HPV-11 humoral responses (IgG titers and memory B cells) in subjects who received the Gardasil
vaccine approximately six years earlier, which implied a sustainable and strong immunologic response
also against the low-risk HPV types elicited by the quadrivalent vaccine and confirming other
observations [25]. In addition, long-term cross-neutralizing responses against non-vaccine types,
HPV-31 and HPV-45, which lead to approximately 10% of all cervical cancers [55], was determined,
and mainly detected in Cervarix-vaccinated women [44–46]. As expected, for HPV-31 and −45
the neutralization titers appeared to be lower than those for HPV-16 and HPV-18.
The detection of antigen-specific memory B cells might be indicative of a robust and long- lasting
vaccine-induced immune response [56,57], but relatively few studies have examined the proportion
and specificity of memory B cells induced by the HPV vaccines [44,58–62]. Strikingly, our results
show that, while Cervarix induces significantly higher and more persistent antibody responses when
compared to Gardasil, the two vaccines are rather equivalent in inducing memory B-cells; in some
cases, the percentage of subjects with vaccine-specific memory B cells was even superior among
Gardasil vaccinees (Figure 4A). This results in a proportion of Cervarix vaccinated individuals with
circulating antibodies in the absence of detectable memory B cells and, conversely, in a proportion
of Gardasil-vaccinated subjects with memory B cells, but undetectable antibodies (Figure 5).
When naïve B cells are activated after the encounter with their cognate antigen, they become either
memory B cells or plasma cells (PCs), which can be short- or long-lived PCs (SLPCs and LLPCs) [63].
While the magnitude of early humoral responses is determined by both types of PCs, the long-term
maintenance of antibodies is antigen-independent and could last for life [28,63,64], due to the continuous
presence of LLPCs. Whether these are the same PCs generated at priming or are rather derived from
the differentiation of memory B cells into “new” LLPCs is not clear yet. However, recently, it has been
proposed that PCs may survive up to 20 years [65]. In addition, PCs and long-lasting serum
antibodies have also been shown to persist in the absence of memory B cells [28,64,66,67]. Together,
these evidence suggest that circulating antibodies could be detected, regardless of the presence
of memory B cells, as observed in our study for some Cervarix vaccinated women. The independent
regulation of circulating memory B cells and antibodies is usually observed in the case of multiple
exposure to the antigen (persistent infections or recall vaccine doses), to which IgG titers and memory
B cell levels should react differently. We failed to observe in some groups a correlation between
circulating IgG titers and memory B cell numbers, consistent with the hypothesis that memory B cells
and LLPCs are two independent arms of humoral immunological memory, as also reported for tetanus
and diphteria vaccines and for persistent infections, such as EBV and VZV [43,68].
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In contrast, it has also been suggested that memory B cells could differentiate (by non-specific stimuli,
such as TLRs) into secreting PCs. Consequently, the persistence of IgG would depend on the presence
of memory B cells, with a positive correlation between circulating antibody levels and memory B
cells [42,43], as in acute infections (Measles, Mumps, and Rubella) and live vaccines (smallpox) [43,69].
We observed a correlation between memory B cells and IgG, for HPV-16, in 16–20 y women for both
vaccines, while, for HPV-18, in 10–12 y women only for Gardasil (Figure 6). The lack of a clear
pattern suggests that this correlation is an epiphenomenon (circulating IgG and memory B cells
share the same stability, even if independently maintained), rather than the conversion of memory
B cells into PCs. To support this idea, in the groups where a correlation was observed, we found
subjects with IgG, but not memory B cells (for HPV-16 in Cervarix vaccinated, 16–20 y) and memory
B cells without IgG (for HPV-16 in Gardasil vaccinated, 16–20 y women and for HPV-18 in Gardasil
vaccinated, 10–12 y women). Other studies have, instead, shown a positive correlation between HPV
vaccine IgG and memory B cells. This discrepancy could derive by differences in the age of vaccinees,
the number of vaccine doses or the time of analysis after vaccination [61,70]. In fact, we have also
observed a correlation between HPV-16 and HPV-18 IgG and memory B cells in a cohort of 10–12 y
Cervarix vaccinated girls analyzed 1–6 months after the third immunization (Table 1). The correlation
appears to be lost when immune responses are analyzed 4–6 years after vaccination in a different
cohort of girls vaccinated Cervarix at 10–12 y. Together, these data indicate that HPV vaccination
might induce both PCs (including LLPCs) and memory B cells, to a similar extent. However, the two
B lymphocyte subsets follow different maintenance kinetics and the correlation is lost over time.
The loss of circulating antibodies but not of memory B cells is not uncommon, as also observed for other
vaccines, such as against HBV [28,71].
Our observations showed a different pattern between Gardasil and Cervarix. Therefore,
it is possible that, during the priming of naïve B cells, Cervarix prompts their differentiation into LLPCs
while Gardasil toward memory B cells. The half-life of LLPCs is determined at priming of naïve B
cells [72], influencing the antibody persistence [73]. The induction of T follicular helper cells (TFH),
the secretion of several cytokines (including IFNγ) and the expression of key transcription factors
favor the generation and maturation of antibody secreting cells [74]. The use of MPL in combination
with Al(OH)3, in contrast to Al(OH)3 alone, induced higher titers of long-lasting binding and nAbs,
while the results of memory B cells were less clear [75]. MPL might also stimulate IFNγ secretion [50,76]
and enhance the recruitment of TFH [77]. Notably, Cervarix and Gardasil have shown to induce
different subsets of TFH [78] and differently affect PD1 and ICOS expression on TFH [78]. The induction
of a precise TFH pattern and the stronger antigenic stimulation and pro-inflammatory cytokine secretion
by MPL might account for the preferential differentiation of primed naïve B cells into PCs [79,80],
rather than into memory B cells, after Cervarix vaccination, thus also explaining the high antibody
titers in the absence of circulating memory B cells.
In conclusion, our results show that the induction and maintenance of circulating antibodies was
higher in Cervarix vaccine subjects, and their persistence was memory B cell-independent. However,
Gardasil differentiates naïve B cells more toward a memory phenotype. Our results suggest a key role
for memory B-cell in protection from HPV when considering that its clinical effectiveness has been
shown to persist for at least 10 years [24].
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